Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non-small Cell Lung Cancer”

165 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 165 results

Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Large-scale testing (Phase 3)Study completedNCT01639001
What this trial is testing

Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Pfizer 207
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06282536
What this trial is testing

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Who this might be right for
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 20
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Not applicableStudy completedNCT06339554
What this trial is testing

Alectinib-induced Endocrine Toxicity

Who this might be right for
NSCLC Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Not applicableStudy completedNCT04351334
What this trial is testing

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Who this might be right for
Non-Small-Cell Lung Carcinoma
Pfizer 161
Testing effectiveness (Phase 2)Looking for participantsNCT07354061
What this trial is testing

Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Tang-Du Hospital 20
Not applicableStudy completedNCT04887519
What this trial is testing

Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 39
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Early research (Phase 1)UnknownNCT02695550
What this trial is testing

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Centaurus Biopharma Co., Ltd. 40
Early research (Phase 1)Study completedNCT03420742
What this trial is testing

Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Who this might be right for
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
Takeda 24
Next Page